Ava

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ava

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral tablet
Pharmacological Class Combination Hormonal Contraceptive (CHC)
Common Use Prevention of pregnancy (Contraception)
Origin Synthetic (Analogue of natural hormones)

Defining Ava: What Type of Combination Medicine Is It?

Ava is a prescription-only, synthetic medication classified as a Combined Oral Contraceptive (COC), taken via the oral route in tablet form. This classification places it within the broader Combination Hormonal Contraceptive (CHC) pharmacological class, signifying that it utilizes a combination of two distinct hormone types to suppress fertility. Combined oral contraceptives are a reversible method of birth control available to women of reproductive age. This medication is recognized as a standard form of modern, reversible family planning.

Composition and Form: The Combination of Ethinyl Estradiol and Levonorgestrel

The active pharmaceutical composition of Ava consists of the two generic ingredients: Ethinyl Estradiol and Levonorgestrel. Ethinyl Estradiol is a synthetic estrogen, while Levonorgestrel is a synthetic progestin. This specific combination, utilizing a second-generation progestin, is a key feature that differentiates it from newer formulations containing third- or fourth-generation progestins. Fixed-dose combination pills containing these two specific ingredients have an established safety profile and efficacy. The combination of these two hormones is a reliable choice for contraception. The final product is a combination product where these ingredients are integrated into solid excipients to form the necessary tablet for administration.

General Purpose: The Primary Goal of Taking Ava

The general therapeutic purpose of Ava is the reliable prevention of pregnancy (contraception) in females of reproductive potential. This combination is typically intended for daily, continuous management for those seeking control over their family planning. This continuous hormonal management defines the medication's utility as a planned method of birth control that works by modulating the body's hormonal signals to inhibit the reproductive process.

Regulatory References

  1. NIH: Combined Oral Contraceptives
  2. MedlinePlus: Birth control pills - combination

What side effects are possible with Ava?

Official Adverse Reactions and Safety Profile

The safety profile of Ava (Ethinyl Estradiol/Levonorgestrel) is established in official regulatory documents, detailing possible adverse effects, their frequencies, and documented serious risks. This information is classified by System-Organ-Classes (SOC) to organize where effects may manifest in the body, such as Gastrointestinal Disorders, Nervous System Disorders, and Reproductive System and Breast Disorders.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their documented incidence:

  • Very Common Reactions: May include headache and intermenstrual bleeding or spotting, which is often observed during the initial cycles of use.
  • Common Reactions: Nausea, abdominal pain, weight gain, breast pain, mood changes, depression, and migraine are frequently listed in regulatory documents.
  • Rare Reactions: Adverse events classified as rare include hypersensitivity reactions and, most critically, arterial and venous thromboembolic events, such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. The risk of these serious vascular events is associated with long-term use, especially in women with pre-existing risk factors.

Safety Constraints and Special Populations

Regulatory labeling specifies high-level constraints for use. The medicine is contraindicated for individuals with current or a history of thromboembolic disorders or severe hepatic disease due to the drug's metabolism. Contraindications also include known or suspected breast cancer and undiagnosed abnormal genital bleeding. These constraints define the patient populations for whom the risk of use outweighs the established safety profile, strictly adhering to regulatory limitations.

Overdose and Emergency Response

The official regulatory profile for an overdose of Ava (Ethinyl Estradiol/Levonorgestrel) is defined by a specific statement on clinical severity. Authorities have formally documented that acute ingestion of doses exceeding the prescribed regimen has not resulted in reports of serious ill effects. This finding is consistent across the documented profile, including cases involving ingestion by children.

The documented clinical manifestations of overdose are limited to anticipated hormonal and gastrointestinal effects. The official labeling specifies that females may experience withdrawal bleeding, and the overdose may be accompanied by nausea. The lack of reported serious outcomes means that urgent medical intervention is not explicitly mandated by the regulatory overdose section for the occurrence of these primary, documented symptoms alone.

Regarding clinical management, regulatory documents confirm that there is no specific antidote known or available for this overdose combination. Consequently, the only required intervention is strictly symptomatic and supportive treatment. This supportive care is directed at managing the resulting manifestations, such as nausea or withdrawal bleeding, until symptoms subside naturally, as defined by the official prescribing information.

Therapeutic Uses of Ava

What Ava Treats: Main Uses and Benefits

Ava (Ethinyl Estradiol/Levonorgestrel) is applied across key therapeutic domains where hormonal stability supports symptom management and patient comfort. The combined pill formulation is commonly used for its primary role and its established non-contraceptive benefits, which address a range of patient symptoms. Combined pills are recognized for both their contraceptive effect and their ability to address menstrual and hormonal disorders.


Essential for Reliable Contraception and Reproductive Control

This primary domain focuses on providing reliable pregnancy prevention for females of reproductive potential. The medication assists with stable, planned family planning, contributing to patient control over reproductive timing.

“Ava plays a role in managing symptoms related to severe cramping pain, heavy bleeding, and hormonal skin issues.”


Managing Menstrual Symptoms and Cycle Predictability

Ava is relevant for managing conditions characterized by symptoms that interfere with daily functioning, specifically severe cramping pain (dysmenorrhea) and excessively heavy menstrual bleeding (menorrhagia). This supports the management of symptom clusters that require supportive assistance, including cycle regulation. Indications commonly managed include pregnancy prevention, heavy periods, painful cramps, and moderate acne vulgaris. It helps establish a predictable menstrual rhythm and may help ease the overall symptom burden from these intense, cyclical manifestations.


Quick Fact: Managing Cyclical Discomfort and Skin Manifestations

Ava is commonly used to help with symptoms driven by systemic imbalance, specifically moderate-to-severe acne vulgaris, and supports the management of skin manifestations, contributing to improved comfort related to physical discomfort and cosmetic strain.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls - NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Ava?

The population eligibility for Ava (Ethinyl Estradiol/Levonorgestrel) is strictly defined by regulatory authorities to minimize specific health risks, focusing on an individual's vascular risk profile, history of cancer, and liver function.

Ava is indicated only for females of reproductive potential for the prevention of pregnancy. Use is limited by developmental stage; it is only indicated after menarche (onset of natural menstrual cycles) and is not indicated for postmenopausal women.

Contraindicated Populations

Use of Ava is absolutely contraindicated (prohibited) in individuals with specific high-risk conditions, including:

  • Cardiovascular and Thrombotic Risk: History of or current venous or arterial thrombotic disease (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Coronary Artery Disease) or inherited hypercoagulopathies (e.g., Factor V Leiden).
  • Lifestyle/Age Constraint: Smokers over age 35.
  • Oncologic/Hepatic Risk: History of breast cancer or other hormone-sensitive cancers, severe liver disease/tumors, or acute viral hepatitis.
  • Clinical States: Known or suspected pregnancy, uncontrolled hypertension, or undiagnosed abnormal uterine bleeding.

Condition-Based Restrictions

Certain states require temporary discontinuation or caution:

  • Surgery: Use must be discontinued at least four weeks before and held for two weeks after major surgery.
  • Postpartum: Initiation is restricted to no earlier than four weeks after delivery in non-breastfeeding women.
  • Lactation: Use is not recommended for nursing mothers.

What should I know about interactions with other medicines?

Ava Interactions with other medicines and products

The official regulatory profile for this combination medicine structures interaction information into specific classifications based on the resulting effect on the active ingredients' concentrations.

Documented Interaction Classifications

Classification Official Regulatory Constraint
Contraindicated Combinations The co-administration of Ava is formally prohibited with certain Hepatitis C Virus (HCV) drug regimens (e.g., Ombitasvir/paritaprevir/ritonavir) and Tranexamic Acid due to documented risks.
Exposure-Decreasing Interactions Co-use with strong enzyme inducers, such as Rifampin, select anticonvulsants (e.g., Phenytoin), and the herbal product St. John’s wort, can significantly accelerate metabolism and reduce the plasma concentrations of the hormonal components.
Exposure-Increasing Interactions Co-administration with certain CYP3A inhibitors (e.g., Azole antifungals) or substances like Grapefruit juice may slow the breakdown of the hormones, leading to increased systemic exposure.

Specific Interaction Constraints

One interaction involves the bile acid sequestrant Colesevelam, which requires a mandatory separation of administration by four or more hours to mitigate a documented reduction in Ethinyl Estradiol absorption. Furthermore, the regulatory labeling notes that systemic exposure may not be complete if severe vomiting or diarrhea occurs within three to four hours after tablet intake. Certain co-administered medicines, such as Lamotrigine, may have their plasma concentrations reduced when taken concurrently with Ava, which is noted as a clinically significant pharmacokinetic change. This information defines the parameters for concurrent use as documented by government health authorities.

Mechanism of Action

Mechanism of Action

Ava functions as a selective antagonist of the C5a receptor ( C5aR1), a protein found primarily on the surface of circulating inflammatory cells, such as neutrophils and monocytes.

This antagonistic binding prevents the endogenous inflammatory mediator C5a—a fragment of the complement system—from activating the receptor. By blocking this specific interaction, Ava inhibits the C5a-mediated signaling cascade, which normally triggers the adhesion and directional movement (chemotaxis) of these immune cells.

The resulting inhibition of immune cell activation and migration alters the cellular response at the site of vascular inflammation. This localized effect modulates the severe interaction between neutrophils and the microvasculature, influencing the physiological adjustment within affected systems without broadly suppressing the entire immune response.

Dosage and Administration Information

Instruction Map: How to use Ava — Administration Guidelines

This map consolidates the procedural requirements for administering Ava (Ethinyl Estradiol/Levonorgestrel).


Administration Scope

Feature Instruction
Route of administration Oral route (by mouth).
Dosing schedule One tablet daily taken continuously for the duration of the cycle. Regimens are structured as 28-day cycles or 91-day extended cycles.
Timing in relation to meals The tablet may be taken without regard to meals; the critical instruction is consuming it at the same time every day.
Preparation requirements None required; the medicine is administered directly as an oral tablet.
Age-group administration rules The standard regimen is used for postmenarchal females. The medicine is not indicated for postmenopausal women.
Missed-dose rules If a single active tablet is missed, it must be taken as soon as remembered. Specific protocols apply based on the number of missed tablets and the week of the cycle.
Special procedural conditions Postpartum Initiation: Treatment must not begin earlier than four weeks after delivery in non-breastfeeding women. Gastrointestinal Distress: Follow the instructions for missed tablets if vomiting or severe diarrhea occurs, and use additional non-hormonal contraception.

Instruction Classifications

Classification Detail
Administration method type Oral.
Frequency pattern Daily.
Use-context constraints Must be taken sequentially following the specific order indicated on the blister packaging. Non-hormonal back-up is required for the first seven consecutive days when starting on a Sunday or if a sequence is disrupted.

Resulting Procedural Structure

Step sequence:

  • Take one tablet daily by mouth at the same time every day.
  • Follow the designated order of tablets on the blister pack, proceeding through the entire cycle duration (28 days or 91 days).
  • Start the next cycle pack immediately after the last tablet in the previous cycle is finished, without interruption.

Connection to the overall use protocol: The instructions establish a precise, time-dependent protocol based on continuous daily administration and strict tablet sequencing. This procedural structure governs the necessary pattern of active and inactive hormone intake across repeating 28-day or 91-day cycles. Adherence to the daily timing and the prescribed order is the required means of administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ava


Evidence for Reliable Prevention of Pregnancy (Contraception)

Research has widely explored the use of combined hormonal contraceptives (CHCs), including the specific combination found in Ava (Ethinyl Estradiol/Levonorgestrel), and was studied as a form of contraception. Studies have been conducted in settings involving generally healthy women of reproductive age, using methods like the Pearl Index to measure outcomes related to the occurrence of pregnancy. The available research base includes a substantial number of Randomized Controlled Trials (RCTs), often comparing different regimens, as well as extensive Post-Marketing Epidemiological Studies that track long-term patterns across large populations. Research has cited the difference between outcomes under perfect conditions and outcomes under typical conditions as a key variable.

Evidence for Managing Menstrual Symptoms

Ava was studied for its role in managing conditions characterized by excessively heavy menstrual bleeding (menorrhagia). The research, often relying on RCTs and systematic evaluations, focuses on measured changes in physical symptoms, specifically menstrual blood loss (MBL) volume and patterns of cycle regularity. Findings describe patterns of change in MBL volume measurement observed in the studied populations compared to control groups.

The research base for severe menstrual cramping (primary dysmenorrhea) involves RCTs and longitudinal observational studies. Studies monitored patient-reported outcomes, specifically changes in pain intensity using standardized scales. Reports described differences in pain intensity scores indicated by participants using combined pills compared to comparison groups.

Evidence for Managing Moderate Acne Vulgaris

Ava was evaluated in research exploring the management of moderate acne vulgaris. Studies for this indication were conducted as RCTs over intermediate to long follow-up durations (typically six months or more). Data show patterns related to changes in total lesion counts and scores on global severity scales over several months. A significant research limitation is that the strongest comparative evidence often relies on studies using combined pills that contain progestins with more pronounced anti-androgenic properties than the one in Ava.

What Is Still Uncertain About Ava

Long-term effects are not fully established for all non-contraceptive symptom-related aspects across multi-year durations. Additionally, research has explored the influence of body mass index (BMI) on the medication’s effectiveness, but data for certain groups remain insufficient. Comparative evidence is lacking for direct head-to-head trials against every other modern contraceptive or symptom management option, meaning many findings rely on generalizations across the combined oral contraceptive class as a whole.

Key Studies & References

  1. Levonorgestrel and Ethinyl Estradiol Tablets USP 0.15mg/0.03 mg - DailyMed (FDA-Approved Labeling for COCs)
  2. Levonorgestrel/Ethinylestradiol 150μg/30μg Tablets (Lupin Limited), WHOPAR part 4 Supplier Submission

Frequently Asked Questions (FAQ)

Common questions about Ava (FAQ)

Q: Why do people say Ava works fast/slow?

A: The timeline for the medicine’s effects depends on its purpose. For contraceptive use, official regulatory documentation defines a period during which a non-hormonal back-up method is noted. For other approved uses, such as managing acne or heavy menstrual bleeding, clinical studies show that changes are typically observed over several menstrual cycles or months of continuous administration.

Q: How long does Ava stay in your system?

A: The time it takes for the concentration of the medicine in the body to be reduced by half (known as the mean elimination half-life) is documented in official pharmacokinetic data as approximately 24 hours. This information defines how quickly the hormonal components are processed by the body after administration.

Q: What is the difference between Ava and a generic version?

A: Regulatory agencies require that a generic version of Ava must contain the exact same active ingredients—Ethinyl Estradiol and Levonorgestrel—at the same strength. Regulatory standards require generic products to meet established criteria demonstrating they perform bioequivalently to the brand-name product.

Q: What should I do if I forget a dose of Ava? (Non-directive, seeking general information)

A: Official administration instructions specify a protocol for a single missed active tablet, which generally involves taking the missed tablet upon remembering. Specific detailed protocols based on the number of missed tablets and the cycle week are fully addressed in the official prescribing information, which should be consulted.

Q: What if I take Ava with a supplement like fish oil or multivitamins?

A: The official regulatory label specifies warnings for certain known drug or herbal interactions, such as with St. John’s wort, because they can affect the level of the active ingredients in the bloodstream. Information on interactions with general vitamins or supplements is typically not listed in the official drug information.

Q: How soon after starting Ava might I notice a change?

A: For contraceptive use, regulatory documentation defines a period during which a non-hormonal back-up method is noted. For other approved uses, such as managing acne or heavy menstrual bleeding, clinical studies show that changes are typically observed over several menstrual cycles or months of continuous administration.

Q: What is the shelf life of Ava?

A: Regulatory documentation, based on stability data, establishes an expiration dating period (shelf life) for the product. This shelf life is determined when the medicine is stored strictly at controlled room temperature. Patients are instructed to refer to the expiration date printed on the packaging for product validity.

Q: How long do the main benefits of Ava typically last after taking a dose?

A: The medicine is designed as a daily-administered oral tablet. The continuous presence of the active ingredients needed to maintain the intended effect is achieved by taking one tablet at the same time every day, as instructed in the official administration protocols.

Q: Can Ava be crushed or split?

A: Ava is manufactured and prescribed as an oral tablet intended to be swallowed whole. Regulatory prescribing information does not describe or recommend specific instructions for crushing or splitting the tablet before administration.

Q: What is the purpose of the different inactive ingredients in Ava?

A: Inactive ingredients, also known as excipients, are substances used in the tablet formulation that do not have an active therapeutic effect. Their purpose is to help ensure the medicine’s stability, create its final physical form, and allow it to be delivered properly into the body.

Q: Can Ava cause [Common Symptom]?

A: The official safety profile, based on regulatory reports, lists common reactions classified under different body systems. Documented adverse reactions include headache, nausea, and vomiting, which are often observed during the initial cycles of use.

Q: Is it true that Ava is hard on the liver?

A: Official regulatory documents define the constraints for use. The medicine is contraindicated (should not be used) in individuals with current or a history of severe liver disease or liver tumors. The official label also describes a protocol where use is discontinued if signs of severe liver issues, like jaundice (yellowing of the skin or eyes), occur.

Q: Can Ava make you feel tired?

A: While tiredness itself is not specifically listed in the common reactions section, the regulatory safety profile does include common nervous system reactions such as headache, migraine, and dizziness, as well as less common mood changes.

Q: Does Ava affect blood pressure?

A: Official documents note that uncontrolled high blood pressure (hypertension) is a contraindication for the medicine’s use. If used by those with well-controlled high blood pressure, the regulatory label specifies that blood pressure should be monitored, and the official labeling describes a protocol where the medication should be discontinued if pressure rises significantly.

Q: Can Ava cause dizziness or lightheadedness?

A: Official labeling lists dizziness and lightheadedness as documented adverse reactions. The regulatory safety profile notes that if signs of serious vascular events occur, immediate medical evaluation is necessary.

Q: Why do some users report [Unusual, Non-Serious Side Effect]?

A: The official safety profile is compiled from documented incidence rates reported in controlled clinical studies and through post-marketing surveillance. This profile captures the effects that are most commonly or reliably reported to regulatory agencies and classifies them by frequency (e.g., Very Common, Common, Rare).

Q: Are the effects of Ava permanent?

A: Ava is officially described in regulatory sources as a reversible method of contraception. The heightened risk of vascular events associated with its use is documented to gradually disappear after the medication is discontinued.

Q: Are there any long-term health risks associated with Ava?

A: Official labeling includes warnings about rare, serious long-term vascular events, such as venous and arterial thromboembolism (blood clots, stroke, heart attack). A documented association with certain liver tumors is also noted in the product information.

Q: Does taking Ava require special monitoring or blood tests?

A: Official labeling specifies that blood pressure should be monitored, especially in those with pre-existing conditions. Additionally, prediabetic and diabetic women taking the medicine are advised to be monitored for carbohydrate and lipid metabolic effects.

Q: How is Ava classified by the FDA?

A: Ava is officially classified by regulatory agencies as a Combined Oral Contraceptive (COC). This means it is a prescription-only medicine that utilizes a combination of two synthetic hormones to prevent pregnancy.

Q: Does Ava cause weight gain or loss?

A: Weight gain is listed in the official safety profile as a common adverse reaction that may occur. Weight change (either gain or loss) and fluid retention are documented as possible effects.

Q: Does Ava interact with herbal remedies?

A: The regulatory label specifies warnings for certain known herbal interactions, such as with St. John’s wort, because they can reduce the level of the active ingredients. Information on interactions with general herbal remedies is usually not listed in official drug information.

Q: Can Ava cause trouble sleeping?

A: While 'trouble sleeping' is not specifically listed in the common reactions section, the official safety profile includes common nervous system effects such as headache and less common mood changes or depression, which can sometimes affect sleep patterns.

How should Ava be stored and disposed of?

Storage and Handling Requirements

Ava tablets must be stored strictly according to official regulatory conditions to maintain their potency and stability. The medication requires storage at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and kept away from excessive heat, moisture, and direct light.

The tablets should remain in the tightly closed container or original blister packaging in which they were dispensed. This combined oral contraceptive must also be stored out of the reach of children, following the mandatory safety instruction found in the product labeling.

Disposal Instructions

Unused or expired tablets should not be flushed down the toilet or thrown into the household trash. Disposal must comply with local regulations and professional guidance. Patients should consult a pharmacist or local authority for information on authorized drug take-back programs or collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ava found in:

A-Z Index: